WuXi AppTec Lab Testing Division’s Bioanalytical Service Unit Passed FDA Inspection

We are pleased to announce that WuXi’s  Lab Testing Division(LTD)’s Bioanalytical facility in Shanghai once again passed US FDA’s bioequivalence (BE) inspection with no 483 observations. The inspectors from FDA thoroughly audited...

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

We are excited to announce that WuXi has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become...

Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial...

We are excited to announce that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders – developed by our...

WuXi Global Forum 2017

10 Jan WuXi Global Forum 2017, now in its fifth year, brings together 1,000 industry leaders to promote new thinking on a global stage as we strive to find transformative models and solutions...

WuXi AppTec Receives Inaugural “Company of the Year” Award from BayHelix

We are honored to announce that WuXi has received the inaugural “Company of the Year” Award from BayHelix. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Artificial Intelligence Poised to Transform the Drug Industry from Laboratory to...

Artificial intelligence (AI) –  which learns from computer algorithms how to unravel complex genomic data, such as gene expression patterns of disease – is...